Abstract
Migraine is one of the most common, life-disabling types of headaches. It receives special attention in therapeutic research aimed at identifying the most appropriate treatment.This study compares the efficacy of oral topiramate and Botox injections in the management of chronic migraine.the study included 215 patients, the average age was 33.3±9.3, 73.49% of them were females, treated in several centers (Iraq, Syria, Egypt, Saudi Arabia), over a period of five years from January 1, 2019 to January 1, 2024.Improvement rates were very close, Botox group showed a slight superiority in reducing the frequency of attacks (p value =0.0001), while regarding to the severity and duration of attacks, there was a slight preponderance of improvement in topiramate group (P value = 0.0001) and (P value = 0. 001) in a row.Only about a third of the study patients (35.35%) rely on Botox injections, the majority of whom were female (72%).Regarding the continued improvement in the modified quality of life questionnaire, the topiramate group recorded an improvement with a statistically significant difference (P value = 0. 001) compared to the Botox group (P value = 0. 054).The occupations most frequently were those who had intellectual jobs (25%)
